Italian multidisciplinary delphi consensus on home management of nausea and vomiting in children with acute

Ruggiero Francavilla1, Fernanda Cristofori1, Gian Luigi Marseglia2,3

  • 1Interdisciplinary Department of Medicine, Pediatric Section, Children's Hospital 'Giovanni XXIII', University of Bari Aldo Moro, Bari, Italy.

Insights

Vomiting in pediatric acute gastroenteritis (AGE) is common. Expert consensus supports cautious antiemetic use, like metoclopramide, for home management in select cases to aid rehydration and reduce distress.

Area of Science:

  • Pediatric Gastroenterology
  • Clinical Pharmacology
  • Evidence-Based Medicine

Background:

  • Vomiting in pediatric acute gastroenteritis (AGE) causes significant distress and hinders oral rehydration.
  • Limited guidance exists for home management and antiemetic use in children, compounded by regulatory issues.

Purpose of the Study:

  • To establish expert consensus on managing vomiting in pediatric AGE.
  • To provide recommendations for the safe and effective use of antiemetics, particularly metoclopramide, in home settings.

Main Methods:

  • A modified Delphi consensus process was employed.
  • A national multidisciplinary panel of 70 Italian pediatricians participated in three phases: literature review, anonymous online rating, and refinement.
  • Twenty-one statements on clinical aspects and antiemetic use were rated using a five-point Likert scale, with consensus defined as ≥80% agreement.

Main Results:

  • All 21 statements achieved consensus (83%-100% agreement).
  • High agreement was reached on the clinical impact of vomiting in AGE, its mechanisms, and metoclopramide safety (dosing, age considerations, counseling).
  • The panel agreed that cautious antiemetic use, especially metoclopramide, can support home management for persistent vomiting if safety protocols are followed.

Conclusions:

  • This Delphi consensus offers practical, expert-backed recommendations for managing nausea and vomiting in pediatric AGE at home.
  • Oral rehydration solutions (ORS) are primary treatment; metoclopramide may be considered for symptom resolution and facilitating rehydration in select cases.
  • Strict risk-benefit assessment and adherence to clinical safeguards are crucial when prescribing antiemetics like metoclopramide.
Abstract

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Pathophysiology of Vomiting01:22

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
4.5K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.9K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.1K